Grey Wolf Therapeutics raised €42M in a Series B round in May 2024. The company is based in Oxford, UK. Investors in the round: Andera Partners, British Patient Capital, Canaan and 4 others. Data as of 7 Aug 2026.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
